Presents timely and authoritative information on the development of precision cancer therapies as applied to hematologic malignancies The Precision Cancer Therapies series focuses on how to understand and translate fundamental basic science into information that can be directly applied to patients to advance care. Each volume of the series integrates the relevant biological concepts and principles necessary for translating this science to practitioners of this science. Precision Cancer Therapies, Volume Two, focuses on sophisticated immunotherapies targeting cancers affecting the blood, bone marrow, and lymph nodes. Edited and authored by the foremost authorities in the field, this comprehensive reference text covers targeting of cell surface receptors, antibody-drug conjugates (ADC), targeting immune checkpoint, targeting macrophages, EBV-directed immunotherapies, tumor-associated antigens (TAA), and chimeric antigen receptor T-cells (CAR-T). Divided into nine sections, Volume Two includes an overview of the history of immunotherapy development in cancer, as well as a concluding section addressing the mechanistic basis and role of immunomodulatory drugs, analytical tools to quantitate immune-mediated effects, and other topics in immunotherapy. Chapters on specific therapeutics or therapeutic classes include a basic explanation of the underlying pathway and target, the pharmacology of the drug/class, relevant preclinical and clinical data, and discussion of clinical management and potential predictive biomarkers of response. This book also: Delivers a definitive, state-of-the-art review of the relevant biology and its importance in the broader context of cancer biology Focuses on agents that mediate cell killing in lymphoma through a variety of immunologic mechanisms Covers FDA-approved drugs and their indications, as well as drugs currently in development Provides information on monotherapy and combination therapy, summary tables of trials, and discussion of toxicity and efficacy Includes boxed sections highlighting major unique points about the information in the chapter Precision Cancer Therapies, Volume Two: Immunologic Approaches for the Treatment of Lymphoid Malignancies, From Concept to Practice is an indispensable resource for medical, scientific, and allied medical professionals, advanced students, and interested general readers with background knowledge in the subject.

Targeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies A thorough compilation of the many scientific breakthroughs in the ongoing development of precision cancer therapies related to lymphoma Targeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies: From Concept to Practice focuses on lymphoma, an area which has seen a remarkable number of breakthroughs in the ongoing development of precision cancer therapies. Each section on a specific biology or class of drugs has an introductory chapter written by an authority in the field, exclusively focused on the science and its relevance to cancer biology. This approach addresses the need for scientists, physicians, and the private sector to understand the broader context of the extraordinary advances that have produced such astonishing advances in the disease. The work primarily focuses on how to understand and translate fundamental principles of basic science into information that can be directly applied to patients – hence the subtitle, From Concept to Practice. To aid in readers’ comprehension, the first page of each chapter contains a box entitled ‘Take Home Points’. This short text will highlight the major unique points about the information contained within the chapter. Some of the key topics addressed in the work are as follows: Biological basis of the lymphoid malignancies: fundamental principles of lymphomagenesis and molecular classification of lymphoid malignancies Targeting programmed cell death: principles for understanding the many types of cell death and promising combinations of drugs targeting apoptosis Targeting the PI3K pathway: understanding the intricacies of this complex biology and precisely how targeted drugs can be leveraged therapeutically Targeting the cancer epigenome: pharmacologic features of drugs targeting the epigenome and future prospects for targeting various aspects of epigenetic control Targeting the tumour proteome: understanding the mechanisms of protein degradation in cancer including both older drugs like proteasome inhibitors, and newer PROTAC based approaches Written primarily for scientists and physicians in both the public and private sectors, Targeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies: From Concept to Practice is a comprehensive reference work for those interested in the growing area of Precision Cancer Therapies. Seamlessly integrating the basic and applied science, this volume will be an indispensable reference for those interested in translating the most important advances in science to innovative novel treatments for patients.

Chick Chorioallantoic Membrane Model and Precision Cancer Therapy, Volume 46 in The Enzymes series, highlights new advances in the field, with this new volume presenting interesting chapters on the history of CAM model development, an overview of various CAM-based cancer models, the chick embryo chorioallantoic membrane as an in vivo experimental model to study multiple myelomak, bioluminescent CAM models for screening drugs against pancreatic cancer, X-ray sensitizer screen, patient derived tumor model for esophageal cancer, renal cancer and metastasis, nanoparticle characterization and tumor targeting, and patient derived tumor model for human nasopharyngeal carcinoma. - Provides the authority and expertise of leading contributors from an international board of authors - Presents the latest release in The Enzymes series

Topics in Anti-Cancer Research covers new developments in the field of cancer diagnosis and drug therapy. Novel drugs as anticancer agents include natural and synthetic phenazirines and other anti-cancer compounds. The series also covers information on the current understanding of the pathology and molecular biology of specific neoplasms. The diversity of research topics published in this book series give broad and valuable perspectives for cancer researchers, clinicians, cancer professionals aiming to develop novel anti-cancer targets and patents for the treatment of various cancers. The topics covered in this volume are: - Peptides can play a major role in combating cancer diseases - Studying of the CLL after treatment using fractal parameter of neoplastic lymphocytes detection (ΛNLD) - Mechanistic insight of rhenium-based compounds as anti- cancer agents - Targeting cancer-specific inflammatory components in cancer therapeutics - Marine natural products as a source of novel anticancer agents: a treasure from the ocean - PDX clinical trial design in anti-cancer research

Cancer still poses a significant challenge in healthcare since traditional treatments often fail to produce desired results and patient outcomes. Conventional therapies, like chemotherapy and radiation, can have substantial side effects and may not always be able to eliminate cancer cells. Moreover, the heterogeneity of tumors and individual responses to treatment create barriers to achieving consistent and long-lasting outcomes. Critical Developments in Cancer Immunotherapy offers a compelling solution to these challenges by delving into the cutting-edge field of cancer immunotherapy. This book provides a comprehensive guide to the latest advancements in harnessing the body's immune system to fight cancer. Focusing on critical strategies like checkpoint inhibitors and CAR T-cell therapy, the book provides insights into novel approaches that offer greater precision and effectiveness in cancer treatment.

Molecular Biomarkers in Cancer Detection and Monitoring of Therapeutics, Volume One, Discovery and Technologies discusses how molecular biomarkers are used to determine predisposition, facilitate detection, improve treatment and offer prevention guidelines for different cancer types. This first volume in the series focuses on techniques and approaches recently developed to assist in the decision of which biomarker to use for specific conditions. Topics covered include circulating tumor cells and circulating tumor DNA, exomes, tumor microenvironment, gene editing, artificial intelligence and robotics. In addition, the book discusses the development and applications of organoids and precision medicine.This book will be a valuable resource for cancer researchers, oncologists, graduate students and members of the biomedical field who are interested in the potential of biomarkers in cancer research. Provides up-to-date information on current molecular biomarkers research for cancer Presents basic research aspects and novel technologies applied in the discovery of new biomarkers Discusses several technologies, including artificial intelligence, robotics, data mining, gene editing, omics and their applicability for specific cancer types

Advances in Clinical Radiology was established to review the year’s most important questions in clinical radiology. A distinguished editorial board, headed by Dr. Frank Miller, identifies key areas of major progress and controversy, and invites preeminent specialists to contribute original articles devoted to these topics. These insightful overviews in radiology bring concepts to a clinical level and explore their everday impact on patient care.

Use THE definitive reference for laboratory medicine and clinical pathology! Tietz Textbook of Laboratory Medicine, 7th Edition provides the guidance necessary to select, perform, and evaluate the results of new and established laboratory tests. Comprehensive coverage includes the latest advances in topics such as clinical chemistry, genetic metabolic disorders, molecular diagnostics, hematology and coagulation, clinical microbiology, transfusion medicine, and clinical immunology. From a team of expert contributors led by Nader Rifai, this reference includes access to wide-ranging online resources on Expert Consult — featuring the comprehensive product with fully searchable text, regular content updates, animations, podcasts, over 1300 clinical case studies, lecture series, and more. - Authoritative, current content helps you perform tests in a cost-effective, timely, and efficient manner; provides expertise in managing clinical laboratory needs; and shows how to be responsive to an ever-changing environment. - Current guidelines help you select, perform, and evaluate the results of new and established laboratory tests. - Expert, internationally recognized chapter authors present guidelines representing different practices and points of view. - Analytical criteria focus on the medical usefulness of laboratory procedures. - Use of standard and international units of measure makes this text appropriate for any user, anywhere in the world. - Elsevier eBooks+ provides the entire text as a fully searchable eBook, and includes animations, podcasts, more than 1300 clinical case studies, over 2500 multiple-choice questions, a lecture series, and more, all included with print purchase. - NEW! 19 additional chapters highlight various specialties throughout laboratory medicine. - NEW! Updated, peer-reviewed content provides the most current information possible. - NEW! The largest-ever compilation of clinical cases in laboratory medicine is included with print purchase on Elsevier eBooks+. - NEW! Over 100 adaptive learning courses included with print purchase on Elsevier eBooks+ offer the opportunity for personalized education.

Colorectal cancer (CRC) is a major global health challenge as the third leading cause for cancer related mortalities worldwide. Despite advances in therapeutic strategies, the five-year survival rate for CRC patients has remained the same over time due to the fact that patients are often diagnosed in advanced metastatic stages. Drug resistance is another common reason for poor prognosis. Researchers are now developing advanced therapeutic strategies such as immunotherapy, targeted therapy, and combination nanotechnology for drug delivery. In addition, the identification of new biomarkers will potentiate early stage diagnosis. This book is the third of three volumes on recent developments in colorectal diagnosis and therapy. Each volume can be read on its own, or together. Each volume focuses on different novel therapeutic advances, biomarkers, and identifies therapeutic targets for treatment. Written by leading international experts in the field, coverage addresses the role of diet habits and lifestyle in reducing gastrointestinal disorders and incidence of CRC. Chapters discuss current and future diagnostic and therapeutic options for colorectal cancer patients, focusing on immunotherapeutics, nanomedicine, biomarkers, and dietary factors for the effective management of colon cancer.